IL144259A0 - Methods for making proteins containing free cysteine residues - Google Patents
Methods for making proteins containing free cysteine residuesInfo
- Publication number
- IL144259A0 IL144259A0 IL14425900A IL14425900A IL144259A0 IL 144259 A0 IL144259 A0 IL 144259A0 IL 14425900 A IL14425900 A IL 14425900A IL 14425900 A IL14425900 A IL 14425900A IL 144259 A0 IL144259 A0 IL 144259A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- cysteine residues
- proteins containing
- containing free
- free cysteine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 235000018102 proteins Nutrition 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 108091006006 PEGylated Proteins Proteins 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11604199P | 1999-01-14 | 1999-01-14 | |
| PCT/US2000/000931 WO2000042175A1 (en) | 1999-01-14 | 2000-01-14 | Methods for making proteins containing free cysteine residues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144259A0 true IL144259A0 (en) | 2002-05-23 |
Family
ID=22364893
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14425900A IL144259A0 (en) | 1999-01-14 | 2000-01-14 | Methods for making proteins containing free cysteine residues |
| IL144259A IL144259A (en) | 1999-01-14 | 2001-07-11 | Methods for making proteins containing free cysteine residues |
| IL194483A IL194483A0 (en) | 1999-01-14 | 2008-10-02 | Methods for making proteins containing free cysteine residues |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL144259A IL144259A (en) | 1999-01-14 | 2001-07-11 | Methods for making proteins containing free cysteine residues |
| IL194483A IL194483A0 (en) | 1999-01-14 | 2008-10-02 | Methods for making proteins containing free cysteine residues |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP2305804B1 (de) |
| JP (3) | JP2002534119A (de) |
| KR (1) | KR100731826B1 (de) |
| CN (1) | CN1210400C (de) |
| AT (1) | ATE526401T1 (de) |
| AU (2) | AU775937B2 (de) |
| BR (2) | BR0008759B1 (de) |
| CA (1) | CA2359345A1 (de) |
| ES (1) | ES2373093T3 (de) |
| IL (3) | IL144259A0 (de) |
| NZ (1) | NZ513077A (de) |
| WO (1) | WO2000042175A1 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| BR0008759B1 (pt) | 1999-01-14 | 2014-03-11 | Bolder Biotechnology Inc | Métodos para a produção de proteinas contendo resíduos de cisteina livre |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| EP1284987B1 (de) | 2000-05-16 | 2007-07-18 | Bolder Biotechnology, Inc. | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
| EP1333036B1 (de) | 2000-10-16 | 2009-01-21 | Chugai Seiyaku Kabushiki Kaisha | Peg-modifiziertes erythropoietin |
| ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| ES2361824T3 (es) | 2000-12-20 | 2011-06-22 | F. Hoffmann-La Roche Ag | Conjugados de eritropoyetina (epo) con polietilenglicol (peg). |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| WO2002055532A2 (en) * | 2001-01-11 | 2002-07-18 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
| WO2002069232A2 (en) * | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| PL374354A1 (en) * | 2001-11-20 | 2005-10-17 | Pharmacia Corporation | Chemically-modified human growth hormone conjugates |
| GB2389115B (en) * | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
| AU2003241279A1 (en) * | 2002-03-26 | 2003-10-13 | Biosynexus Incorporated | Antimicrobial polymer conjugates |
| EP1382352A1 (de) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| PA8588901A1 (es) * | 2002-11-20 | 2005-02-04 | Pharmacia Corp | Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion |
| AU2003303635B2 (en) | 2002-12-26 | 2009-07-23 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
| CN102139114A (zh) | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | 聚合物-因子viii部分缀合物 |
| SE526214C2 (sv) * | 2003-02-28 | 2005-07-26 | Amersham Biosciences Ab | Ett sätt att generera metallkelaterande affinitetsligander |
| JP4753867B2 (ja) | 2003-04-15 | 2011-08-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体 |
| EP1641481A4 (de) * | 2003-05-30 | 2008-10-15 | Centocor Inc | Bildung von neuen erythropoietin-konjugaten unter verwendung von transglutaminase |
| EA009988B1 (ru) * | 2003-07-29 | 2008-04-28 | Арес Трейдинг С.А. | Применение человеческого гормона роста при множественной системной атрофии |
| JP2008500275A (ja) * | 2003-12-31 | 2008-01-10 | セントカー・インコーポレーテツド | Ｎ末端の遊離チオールを有する新規な組み換えタンパク質 |
| WO2005113592A2 (en) | 2004-05-19 | 2005-12-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| KR20070042567A (ko) * | 2004-08-31 | 2007-04-23 | 파마시아 앤드 업존 캄파니 엘엘씨 | 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법 |
| PT2371856T (pt) | 2004-11-12 | 2022-08-12 | Bayer Healthcare Llc | Modificação de fviii direcionada a sítio |
| EP1848461A2 (de) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Konjugate einer epo-gruppierung und eines polymers |
| WO2007044083A2 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
| KR100694994B1 (ko) | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
| JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
| KR100735784B1 (ko) | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
| KR20090013816A (ko) * | 2006-05-24 | 2009-02-05 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체 |
| EP2102355B1 (de) * | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung |
| CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| JP5792951B2 (ja) | 2010-12-16 | 2015-10-14 | キヤノン株式会社 | 振動型アクチュエータの制御装置 |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| EP3412314A1 (de) * | 2011-05-27 | 2018-12-12 | Baxalta GmbH | Mit polysialsäure konjugierte therapeutische proteine und verfahren zur herstellung davon |
| CN104220097B (zh) * | 2011-12-19 | 2019-08-09 | 建新公司 | 促甲状腺激素组合物 |
| CN103184208B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用 |
| SG11201502511YA (en) * | 2012-09-04 | 2015-05-28 | Republic Polytechnic | Isolated oligonucleotides, methods and kits for detection, identification and/or quantitation of chikungunya and dengue viruses |
| WO2015086853A1 (en) * | 2013-12-13 | 2015-06-18 | Novo Nordisk Health Care Ag | Method for thioether conjugation of proteins |
| PE20170908A1 (es) * | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| EP3294322A4 (de) * | 2015-05-15 | 2018-12-12 | Medimmune, LLC | Verbesserte uricasesequenzen und behandlungsverfahren |
| EP3334760B1 (de) * | 2015-08-12 | 2021-03-10 | Pfizer Inc | Antikörpercysteine mit kappe und ohne kappe und deren verwendung in antikörper-arzneimittel-konjugation |
| AU2016324463B2 (en) | 2015-09-17 | 2022-10-27 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| CN106924753B (zh) * | 2015-12-30 | 2021-11-09 | 北京大学 | 制备蛋白质-聚氨基酸环状偶联物的方法 |
| AU2018218548A1 (en) * | 2017-02-08 | 2019-07-25 | Pfizer Inc. | Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation |
| CN111172184A (zh) * | 2020-03-10 | 2020-05-19 | 大连理工大学 | 一种基于基因修饰得到人重组干扰素的融合基因、融合蛋白及其制备方法 |
| CN112812963A (zh) * | 2021-01-28 | 2021-05-18 | 美康生物科技股份有限公司 | 一种总同型半胱氨酸测试卡 |
| CN115417917A (zh) * | 2021-05-30 | 2022-12-02 | 中国科学院上海药物研究所 | 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5016321B1 (de) * | 1969-05-10 | 1975-06-12 | ||
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| DE3540076A1 (de) * | 1985-11-12 | 1987-05-14 | Boehringer Mannheim Gmbh | Verfahren zur stabilisierung von creatinkinase |
| JPH01132598A (ja) * | 1987-10-14 | 1989-05-25 | Pitman Moore Inc | 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法 |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5130418A (en) * | 1989-05-02 | 1992-07-14 | California Biotechnology Inc. | Method to stabilize basic fibroblast growth factor |
| US5235043A (en) * | 1990-04-06 | 1993-08-10 | Synergen, Inc. | Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5837539A (en) † | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| DE4113750A1 (de) * | 1991-04-26 | 1992-10-29 | Boehringer Mannheim Gmbh | Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen |
| US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| EP0633934A1 (de) † | 1992-04-02 | 1995-01-18 | Imperial Cancer Research Technology Limited | Modifizierte Zellen und Behandlungsverfahren |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| JPH08506095A (ja) * | 1992-11-25 | 1996-07-02 | アムジェン ボールダー インコーポレイテッド | 改変インシュリン様成長因子 |
| EP0708655A1 (de) | 1993-04-07 | 1996-05-01 | Amgen Boulder Inc. | Methoden zur Vewendung des insulinartigenWachstumsfaktor-bindendes Proteins |
| EP0730660A4 (de) * | 1993-10-29 | 1998-02-25 | Incyte Pharma Inc | Chimäre proteine protease nexin-1 varianten enthaltend |
| US6207640B1 (en) * | 1994-04-07 | 2001-03-27 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| AU2601895A (en) * | 1994-05-24 | 1995-12-18 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| CA2172273A1 (en) * | 1994-07-29 | 1996-02-15 | Geert Maertens | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| CN1168678A (zh) * | 1994-10-13 | 1997-12-24 | 安姆根有限公司 | 用kgf治疗糖尿病的方法 |
| WO1996036362A1 (en) * | 1995-05-16 | 1996-11-21 | Prizm Pharmaceuticals, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| JPH11514223A (ja) * | 1995-09-22 | 1999-12-07 | イムノメディクス，インコーポレイテッド | 複数のジスルフィド結合を有する組換えタンパク質およびそのチオール置換複合体 |
| GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| CA2615918C (en) * | 1997-02-21 | 2013-11-26 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| BR0008759B1 (pt) | 1999-01-14 | 2014-03-11 | Bolder Biotechnology Inc | Métodos para a produção de proteinas contendo resíduos de cisteina livre |
| KR20070042567A (ko) | 2004-08-31 | 2007-04-23 | 파마시아 앤드 업존 캄파니 엘엘씨 | 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법 |
| CN101495155A (zh) | 2006-07-07 | 2009-07-29 | 诺沃-诺迪斯克保健股份有限公司 | 新的蛋白结合物及其制备方法 |
| CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
| CN105593242B (zh) | 2013-07-11 | 2020-11-06 | 斯克利普斯研究所 | 卷曲螺旋免疫球蛋白融合蛋白及其组合物 |
-
2000
- 2000-01-14 BR BRPI0008759-9A patent/BR0008759B1/pt not_active IP Right Cessation
- 2000-01-14 NZ NZ513077A patent/NZ513077A/xx not_active IP Right Cessation
- 2000-01-14 KR KR1020017008951A patent/KR100731826B1/ko active IP Right Grant
- 2000-01-14 CA CA002359345A patent/CA2359345A1/en not_active Abandoned
- 2000-01-14 AT AT00902412T patent/ATE526401T1/de not_active IP Right Cessation
- 2000-01-14 EP EP20100012486 patent/EP2305804B1/de not_active Revoked
- 2000-01-14 EP EP00902412.6A patent/EP1144613B2/de not_active Expired - Lifetime
- 2000-01-14 JP JP2000593732A patent/JP2002534119A/ja active Pending
- 2000-01-14 BR BR122013003013A patent/BR122013003013B8/pt not_active IP Right Cessation
- 2000-01-14 AU AU24133/00A patent/AU775937B2/en not_active Ceased
- 2000-01-14 IL IL14425900A patent/IL144259A0/xx unknown
- 2000-01-14 WO PCT/US2000/000931 patent/WO2000042175A1/en active Application Filing
- 2000-01-14 ES ES00902412T patent/ES2373093T3/es not_active Expired - Lifetime
- 2000-01-14 CN CNB008088411A patent/CN1210400C/zh not_active Expired - Fee Related
-
2001
- 2001-07-11 IL IL144259A patent/IL144259A/en not_active IP Right Cessation
-
2004
- 2004-11-19 AU AU2004231217A patent/AU2004231217B2/en not_active Ceased
-
2008
- 2008-10-02 IL IL194483A patent/IL194483A0/en unknown
-
2010
- 2010-09-02 JP JP2010196790A patent/JP5517844B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-20 JP JP2014007656A patent/JP2014064594A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2413300A (en) | 2000-08-01 |
| BR122013003013B8 (pt) | 2021-07-06 |
| BR0008759A (pt) | 2002-08-06 |
| EP1144613B1 (de) | 2011-09-28 |
| AU2004231217B2 (en) | 2008-02-28 |
| CA2359345A1 (en) | 2000-07-20 |
| KR100731826B1 (ko) | 2007-06-22 |
| NZ513077A (en) | 2004-03-26 |
| IL194483A0 (en) | 2011-08-01 |
| JP2010280714A (ja) | 2010-12-16 |
| EP1144613B2 (de) | 2020-05-06 |
| JP5517844B2 (ja) | 2014-06-11 |
| ATE526401T1 (de) | 2011-10-15 |
| BR0008759B1 (pt) | 2014-03-11 |
| EP1144613A4 (de) | 2002-10-29 |
| JP2014064594A (ja) | 2014-04-17 |
| CN1210400C (zh) | 2005-07-13 |
| WO2000042175A1 (en) | 2000-07-20 |
| EP2305804B1 (de) | 2015-05-06 |
| CN1355842A (zh) | 2002-06-26 |
| EP1144613A1 (de) | 2001-10-17 |
| BR122013003013B1 (pt) | 2015-06-30 |
| ES2373093T3 (es) | 2012-01-31 |
| EP2305804A1 (de) | 2011-04-06 |
| JP2002534119A (ja) | 2002-10-15 |
| KR20020011364A (ko) | 2002-02-08 |
| AU775937B2 (en) | 2004-08-19 |
| AU2004231217A1 (en) | 2004-12-23 |
| IL144259A (en) | 2009-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL194483A0 (en) | Methods for making proteins containing free cysteine residues | |
| AU7485301A (en) | Methods for refolding proteins containing free cysteine residues | |
| DK0469074T3 (da) | Cystein-tilsatte varianter af IL-3 og kemiske modifikationer deraf | |
| RU96115394A (ru) | Производные камптотецина | |
| ES2137511T3 (es) | Compuestos que contienen un aceptor de michael, especialmente derivados de maleimida o acido maleico, directamente o indirectamente conectado a un cromoforo, y su uso en composiciones de proteccion solar de larga duracion. | |
| ATE32728T1 (de) | Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel. | |
| EP0235692A3 (en) | Oligopeptidyl nitrile derivatives, the agents containing them, process for their preparation and their use | |
| ES8501364A1 (es) | Un metodo para la preparacion de nuevos polipeptidos. | |
| DE69025194D1 (de) | Aminosäure-beta-lyase-enzyminhibitoren als deodorantien | |
| FI895921A0 (fi) | Enzymhaemmande aminosyraderivat, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning. | |
| EP0384341A3 (de) | Prolinderivate | |
| ATE377000T1 (de) | 5-ht1f agonisten | |
| HUP9802206A1 (hu) | Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához | |
| TR200100125T2 (tr) | Çok döngülü tiyazolidin-2-iliden aminleri, bunların üretimi için yöntemler | |
| DE69104220D1 (de) | Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten. | |
| TW200502235A (en) | Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof | |
| DK0408423T3 (da) | Beskyttelseskompositioner for metaller, fremgangsmåder til fremstilling deraf og fremgangsmåder til beskyttelse af metaller | |
| DE69000259D1 (de) | Pharmazeutische zusammensetzung enthaltend 1-isopropyldihydrolysergsaeure. | |
| JPS5461170A (en) | Preparation of coerulein and its analogs | |
| JPS57176940A (en) | Novel color-developing peptide derivative | |
| ES2054734T3 (es) | Aminoacidos y peptidos glicosilados. | |
| RU99126871A (ru) | Гликоконъюгаты 20(s)-камптотецина | |
| RU2000123696A (ru) | Защищенные пептиды кальцитонина |